Breast cancer subtype (BCS) and lymphovascular invasion (LVI) have both been independently demonstrated as prognostic factors. The objective of this investigation was to evaluate the prognostic power of LVI and lymph node status among BCSs.
From an institutional database, 2017 women with a histopathologically confirmed diagnosis of breast cancer treated between January 2006 and December 2014 were consecutively selected for participation in this study.
Of the 2017 patients with breast cancer in the BCS groups, the highest OS and RFS rates were observed in luminal A subtype (93.6% vs. 95.1%, respectively) and the lowest were observed in TN subtype (85.3% vs. 83.0%, respectively). There were significant differences in OS according to the LVI status between the luminal A, luminal B and luminal HER2 subtypes. There were also a significant difference in the RFS rate of the luminal A, luminal B, luminal HER2 and HER2 subgroup. Therefore, we inferred that there were stronger links with LVI and BCS with regard to OS and RFS rates. Kaplan-Meier analysis showed that there were significant differences in the OS and RFS rates according to the LVI status among the BCS groups. There were significant differences in OS according to the LVI status in the distribution of the luminal A, luminal B, luminal HER2, and TN subtypes. There were also significant differences in the RFS rates among the luminal B, luminal HER2, and HER2 subtypes. On multivariate analysis, after controlling for age, tumor size was independently associated with LVI and lymph node status among all BCS groups. There were significant differences in OS according to the status of lymph node-negative and LVI-positive in the luminal HER2 subtype, as well as lymph node-positive and LVI-positive in the TN subtype. There were also significant differences in RFS according to the status of lymph node-negative and LVI-positive in the luminal A subgroup.
LVI and lymph node status were important prognostic factor for OS and RFS among all BCSs. In lymph node-negative breast cancer, luminal HER2 had greater predictive value for OS, whereas luminal A displayed greater predictability for RFS. In lymph node-positive breast cancer, the TN subtype had greater predictive value for OS.
Clinical trial identification
Legal entity responsible for the study
Tri-Services General Hospital, National Defense Medical Center
All authors have declared no conflicts of interest.